Kalshi launches bets on clinical trials, FDA approvals
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Kalshi announced Thursday it will start taking bets on clinical trials and regulatory approvals, marking its move into biopharma after prior markets in sports, politics, and reality television.
- AppliedXL, a tech company that monitors and predicts the outcomes of clinical trials, is serving as Kalshi's partner on the new markets.
- The launch is starting with a small number of markets chosen in collaboration with AppliedXL.
- Kalshi is described as one of the world's largest prediction market exchanges, and its expansion targets an industry — clinical development and FDA decisions — that has not previously been traded on such platforms.
Why it matters: By opening a prediction-market venue for clinical trial readouts and FDA approval odds starting Thursday with a small initial slate, Kalshi gives biopharma investors, trial sponsors, and industry watchers a new crowd-priced signal on drug development outcomes alongside traditional analyst coverage.
